<DOC>
	<DOCNO>NCT00024349</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy fluorouracil mitomycin use different way stop tumor cell divide stop grow die . Fluorouracil mitomycin may make tumor cell sensitive radiation therapy . It yet know radiation therapy effective without chemotherapy treat bladder cancer . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy part bladder without chemotherapy treat patient stage II stage III bladder cancer .</brief_summary>
	<brief_title>Radiation Therapy With Without Chemotherapy Treating Patients With Stage II Stage III Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy standard volume radiotherapy v reduce volume radiotherapy without synchronous fluorouracil mitomycin patient stage II III ( muscle invasive ) bladder cancer . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , prior neoadjuvant chemotherapy ( yes v ) , intent enter 1 possible 2 randomization study ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients undergo standard radiotherapy daily 5 day week 4 6.5 week . Patients also receive synchronous chemotherapy comprise mitomycin IV day 1 fluorouracil IV continuously day 1-5 16-20 radiotherapy . - Arm II : Patients undergo standard radiotherapy arm I ( without chemotherapy ) . If standard radiotherapy clearly indicate ( e.g. , patient multiple tumor ) patient may randomize standard radiotherapy without chemotherapy ( arm I III ) . If chemotherapy clearly contraindicate , patient randomize standard reduced volume radiotherapy without chemotherapy ( arm III IV ) . Quality life assess baseline , end therapy , 6 12 month post-randomization , annually least 5 year . Patients follow 6 , 9 , 12 month post-randomization least annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 350 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive bladder cancer ( T24a , N0 , M0 ) Adenocarcinoma Transitional cell carcinoma Squamous cell carcinoma Localized muscle invasion surgery image PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) ALT AST less 1.5 time ULN Renal : Glomerular filtration rate great 25 mL/min Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No inflammatory bowel disease No prior malignancy within past 2 year except adequately treat basal cell skin cancer carcinoma situ cervix No prior malignancy uncontrolled systemic disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy pelvis Surgery : See Disease Characteristics No bilateral hip replacements Other : No concurrent metronidazole fluorouracil administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
	<keyword>adenocarcinoma bladder</keyword>
</DOC>